本帖最后由 老马 于 2012-1-13 21:20 编辑
- M$ ?# q1 q+ ?, ` R/ r2 Q1 p: e" C# ]( H) J5 M5 G7 P
爱必妥和阿瓦斯丁的比较7 F+ ^: O1 Q+ }$ b) R+ r
0 S$ n+ ~- Z5 W3 [0 [4 D Nhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" b* _) C& n) G
9 a6 r. u( q0 S" L6 f
6 p" x) k( ]; Q$ Z% Chttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( M8 U) z- Z# l+ t
==================================================
# N4 m& U4 c4 e; z' ` x9 rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% G: i3 b% n- h1 M7 m
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 V; q: [$ Z u- f/ \4 b- N% uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." S: V& y* Z! I4 i% K* u5 F8 \
|